Olr560 inhibitors are a specific class of chemical compounds that interact with the Olr560 receptor, a G protein-coupled receptor (GPCR) involved in olfactory signaling. These inhibitors are designed to modulate the activity of the Olr560 receptor, thereby altering its ability to bind with endogenous or exogenous ligands. The Olr560 receptor is part of a larger family of olfactory receptors that are responsible for detecting a wide array of volatile chemical compounds, playing a crucial role in the sensory perception of smell. By inhibiting the activity of Olr560, these compounds can potentially alter the olfactory signals that are transmitted to the brain, leading to changes in the perception of specific odors.
The chemical structure of Olr560 inhibitors typically involves a complex arrangement of functional groups that allow them to selectively bind to the active site of the Olr560 receptor, blocking its interaction with natural ligands. These inhibitors may vary in their specificity, with some being highly selective for the Olr560 receptor, while others may have broader activity across related olfactory receptors. The development and study of Olr560 inhibitors are of particular interest in the field of olfaction research, as they provide insights into the mechanisms of odor detection and discrimination. Additionally, understanding the structure-activity relationship (SAR) of these inhibitors contributes to the broader knowledge of GPCR function and the molecular dynamics of receptor-ligand interactions within the olfactory system.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MEK 162 | 606143-89-9 | sc-488879 | 10 mg | $306.00 | ||
MEK inhibitor, potentially affecting proteins in the MAPK/ERK pathway. | ||||||
5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine | 1032900-25-6 | sc-505041 | 1 mg | $230.00 | ||
ALK inhibitor, potentially affecting proteins in ALK-driven signaling pathways. | ||||||
MDV3100 | 915087-33-1 | sc-364354 sc-364354A | 5 mg 50 mg | $245.00 $1051.00 | 7 | |
Androgen receptor inhibitor, potentially affecting proteins in androgen signaling pathways. | ||||||
TG101348 | 936091-26-8 | sc-364740 sc-364740A | 5 mg 25 mg | $207.00 $515.00 | 6 | |
Inhibits JAK2, potentially affecting proteins in cytokine signaling pathways. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Proteasome inhibitor, potentially affecting protein degradation and cell cycle regulation. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $182.00 $661.00 $1690.00 | 3 | |
Inhibits multiple tyrosine kinases, including VEGFR, potentially affecting angiogenesis-related proteins. | ||||||
Neratinib | 698387-09-6 | sc-364549 sc-364549A sc-364549B sc-364549C sc-364549D | 5 mg 25 mg 100 mg 500 mg 1 g | $92.00 $214.00 $383.00 $755.00 $1250.00 | 4 | |
EGFR and HER2 inhibitor, potentially affecting proteins in associated signaling pathways. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
EGFR inhibitor, specifically targeting T790M mutation, potentially affecting proteins in mutated EGFR pathways. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Inhibits cyclin-dependent kinases 4 and 6, potentially affecting cell cycle-related proteins. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Inhibits JAK1/2, potentially affecting proteins in cytokine signaling pathways. | ||||||